Key Takeaways JNJ stock stayed above 50- and 200-day SMAs for 8 months, signaling sustained bullish momentum.J&'s growth is driven by Innovative Medicine strength, new drugs, and R&D and M&A spend.JNJ faces Stelara patent loss, China headwinds, and 74,000 talc lawsuits, impacting future outlook.Johnson & Johnson’s (JNJ) stock has remained firmly above its 50-day and 200-day simple moving averages (SMAs) for more than eight months, dating back to mid-July 2025, reflecting sustained investor confidence. Notab ...

Core Insights - AbbVie reported strong fourth-quarter and full-year 2025 results, with significant revenue growth driven by its immunology portfolio and steady contributions from its neuroscience segment [1][2]. Neuroscience Segment Performance - The neuroscience segment generated $10.8 billion in revenue for 2025, accounting for approximately 18% of AbbVie's total revenues, reflecting a nearly 20% year-over-year increase [2][8]. - Key products in this segment, including Botox Therapeutic, Vraylar, Qulipta, and Ubrelvy, experienced double-digit sales growth, while the newer therapy Vyalev contributed $482 million in sales [2][8]. - For 2026, AbbVie anticipates neuroscience revenues to reach $12.5 billion, indicating a 16% growth from 2025, with expectations for Vyalev to exceed $1 billion in global sales [3][8]. Product Pipeline and Future Growth - AbbVie is preparing to expand its neuroscience portfolio with a new oral therapy for Parkinson's disease, tavapadon, which is currently under FDA review [4]. - If approved, tavapadon could enhance AbbVie's presence in the Parkinson's disease market and strengthen the long-term growth potential of its neuroscience segment [4]. Competitive Landscape - Competitors in the neuroscience space include Biogen and Johnson & Johnson, both of which are also focusing on expanding their neuroscience offerings [5][6]. - Biogen is diversifying its portfolio due to declining revenues in its multiple sclerosis franchise, while Johnson & Johnson continues to grow its neuroscience products through acquisitions and new therapies [5][6]. Valuation and Market Performance - AbbVie shares are currently trading at a price/earnings (P/E) ratio of 15.61, which is below the industry average of 18.26, although above its five-year mean of 13.73 [9]. - The Zacks Consensus Estimate for AbbVie's 2026 EPS has increased from $14.31 to $14.54, indicating positive market sentiment [11].

Core Insights - Johnson & Johnson (JNJ) is a significant player in the oncology segment, contributing approximately 27% to total revenues and 42% to the Innovative Medicine segment sales [1] - The company is also strengthening its presence in immunology and neuroscience, which are becoming key contributors to revenue growth outside of oncology [1] Immunology Segment - Sales in the Immunology segment declined by around 12% in 2025 due to the loss of exclusivity of Stelara, which saw a 42% drop in sales [3][8] - Tremfya, another key immunology drug, is partially offsetting this decline, with sales increasing by 41% in 2025, surpassing $5 billion for the first time [3][8] - J&J expects Tremfya to exceed $10 billion in peak-year sales, while Simponi/Simponi Aria sales rose by 22% to $2.7 billion [3][8] - New products and pipeline candidates, such as Imaavy (approved for generalized myasthenia gravis) and Icotyde/icotrokinra (pending approval for plaque psoriasis), are expected to drive long-term growth [4][5] Neuroscience Segment - The Neuroscience segment saw a 10% increase in sales in 2025, driven by new products like Caplyta and Spravato [6][8] - Caplyta generated $700 million in sales, while Spravato recorded $1.7 billion, reflecting a 57% year-over-year increase [6][7][8] - Both Caplyta and other pipeline candidates have the potential to achieve peak sales of $5 billion [7] Overall Growth Strategy - Despite the near-term headwind from Stelara's loss of exclusivity, J&J's expanding immunology portfolio and fast-growing neuroscience franchise are helping to rebalance its growth mix [8][9] - The company is well-positioned for long-term growth with multiple late-stage pipeline candidates in both immunology and neuroscience [9] Competitive Landscape - Key competitors in the immunology space include AbbVie, Eli Lilly, Amgen, Sanofi, and Pfizer [10] - In the neuroscience sector, significant competitors are Biogen, Lilly, and Pfizer [10]

Core Insights - Johnson & Johnson (JNJ) has a diverse revenue stream in its Innovative Medicine division, with sales reaching $60.4 billion in 2025, reflecting a 5.3% operational growth and a 4.1% organic growth despite the loss of exclusivity for Stelara [1][10] Group 1: Sales Performance - The Innovative Medicine segment achieved over $15 billion in sales for three consecutive quarters in 2025, marking the first time it surpassed $60 billion in full-year sales [2] - Key products such as Darzalex, Tremfya, and Erleada contributed significantly to growth, with Darzalex sales increasing by 23.0% to $14.35 billion, Erleada by 19.2% to $3.57 billion, and Tremfya by 40.5% to $5.2 billion [6][9] - The decline in Stelara sales by 41.3% to $6.08 billion in 2025 due to its loss of exclusivity negatively impacted the segment's growth by 1110 basis points [4][5] Group 2: Future Outlook - J&J anticipates accelerated growth in the Innovative Medicine segment in 2026, driven by key products and new launches, with expected growth of 5% to 7% from 2025 to 2030 [7][9] - The company expects a more pronounced impact from new products in 2026, including Rybrevant and Caplyta, following approvals in 2025 [7] - However, the impact of generic competition is expected to intensify in 2026, particularly for Stelara, Simponi, and Opsumit as they lose patent protection [8] Group 3: Competitive Landscape - J&J operates in key areas of immunology and oncology, facing competition from major drugmakers such as Novartis, AstraZeneca, AbbVie, and Amgen [10][11] Group 4: Stock Performance and Valuation - J&J's stock has outperformed the industry, rising 55.6% over the past year compared to an 18.0% increase in the industry [12] - The company's shares are currently trading at a price/earnings ratio of 20.63, higher than the industry average of 18.76 and above its five-year mean of 15.65 [14] - The Zacks Consensus Estimate for 2026 earnings has increased from $11.48 to $11.54, indicating positive sentiment [16]

Core Insights - Neuroscience has historically been viewed as a high-risk area in pharmaceutical R&D, particularly for conditions like Alzheimer's disease and schizophrenia, due to complex pathophysiological mechanisms leading to high failure rates [1] - Recently, there has been a notable shift as the neuroscience sector is gaining momentum, driven by commercial success in Alzheimer's treatments and advancements in technologies such as small molecules, RNAi, cell therapy, and AI [1][6] - The combination of technological breakthroughs and market confidence is prompting multinational corporations (MNCs) to engage in mergers, acquisitions, and collaborations, signaling a potential "gold rush" in neuroscience [1] Industry Trends - The number of clinical trials and transactions in the neuroscience field is increasing, with 138 new drugs currently undergoing 182 clinical trials for Alzheimer's disease, marking a 9% increase from 2024 [2] - Over the past five years, more than 200 new clinical trials have been initiated for Alzheimer's disease, depression, and Parkinson's disease, indicating a growing interest in these areas [5] Market Developments - Confidence in the sector is rising, particularly due to breakthroughs in Alzheimer's treatments, such as Biogen's Leqembi, which achieved sales of $214 million in 2024 and $121 million in Q3 2025, reflecting an 82% year-over-year increase [6] - The approval of diagnostic methods, such as the Elecsys® pTau181 blood test by Roche and Eli Lilly, is enhancing the efficiency of Alzheimer's diagnosis and treatment [7] Technological Innovations - Emerging technologies like brain-computer interfaces and brain stimulation devices are becoming part of the investment narrative in neuroscience, with companies like Neuralink and Synchron conducting human clinical trials [8] - Advances in biomarkers and imaging agents are improving patient stratification in drug development, enhancing predictability of treatment efficacy [8] Policy Support - Significant government investments in brain science initiatives, such as the U.S. "Brain Initiative" with over $4 billion funding from 2014 to 2023, and China's brain plan with a budget exceeding 5 billion yuan, are fostering growth in the sector [8] Treatment Paradigms - The treatment landscape for Alzheimer's is evolving, with new therapies targeting Tau proteins gaining prominence over traditional Aβ-targeting approaches [9] - Innovations in drug delivery methods, such as brain-penetrating antibodies and RNAi technologies, are redefining treatment boundaries in neuroscience [11][12] Conclusion - After decades of exploration, the neuroscience field is experiencing unprecedented research intensity and commercialization, marking the onset of a new "gold rush" in the industry [13]

Core Insights - Johnson & Johnson (J&J) announced a financial outlook for 2026, projecting sales between $100.0 billion and $101.0 billion, surpassing the Zacks Consensus Estimate of $98.5 billion, with adjusted earnings per share expected to be in the range of $11.43 to $11.63 [1][9] Group 1: Innovative Medicine Segment - J&J anticipates accelerated growth in the Innovative Medicine segment in 2026, despite the loss of exclusivity (LOE) for the blockbuster drug Stelara, which negatively impacted growth by 1040 basis points in 2025 [2][3] - Key products such as Darzalex, Tremfya, Spravato, Carvykti, and Erleada, along with new launches like Rybrevant and Caplyta, are expected to drive growth in 2026 [4][5] - The impact of generic competition is expected to increase in 2026 with the introduction of biosimilars for Stelara and generics for Simponi and Opsumit [3][4] Group 2: MedTech Segment - J&J's MedTech business showed improvement with sales rising 4.3% to $33.8 billion in 2025, and stronger growth is expected in 2026 due to increased adoption of new products across various portfolios [6][7] - The company anticipates some challenges from China's volume-based procurement (VBP) program, which is a government-driven cost containment effort [6][7] Group 3: Stock Performance and Valuation - J&J's stock has outperformed the industry, rising 47.3% over the past year compared to a 19.3% increase in the industry [8] - The company's shares are currently trading at a price/earnings ratio of 19.11, higher than the industry average of 18.33 and above its five-year mean of 15.65 [11] - The Zacks Consensus Estimate for 2026 earnings has increased from $11.46 to $11.53, reflecting a positive outlook following J&J's financial projections [13]

Financial Performance - Johnson & Johnson (J&J) reported a 9.1% increase in Q4 2025 sales, reaching $24.56 billion, with net earnings rising by 49.1% to $5.11 billion [1] - For the entire year, sales grew by 6% to $94.2 billion, and full-year earnings per share (EPS) registered at $11.03 [1] - Adjusted net earnings for Q4 2025 were reported at $6.1 billion, up by 21.5% from $4.94 billion in the same period of the prior year [2] - Adjusted diluted EPS increased to $2.46 from the previous year's $2.04, translating to a 20.6% growth [2] - The diluted EPS for Q4 2025 stood at $2.10, up from $1.41 in Q4 2024, reflecting a 48.9% growth [1] Product Innovations and Sector Performance - Significant innovations included approvals for Caplyta in treating major depressive disorder and Rybrevant Faspro plus Lazcluze for non-small cell lung cancer [2] - Operational sales of the global innovative medicine sector increased by 5.3%, driven by products such as Erleada, Darzalex, Carvykti in oncology, and Tremfya in immunology [3] - Medtech saw a worldwide operational sales increase of 5.4%, primarily driven by electrophysiology products and Abiomed in cardiovascular and wound closure products in general surgery [3] Future Outlook - J&J announced guidance for 2026, forecasting estimated reported sales of $100.5 billion and an adjusted EPS of $11.53 at the midpoint [3] - The company emphasized that 2025 was a catapult year, fueled by a strong portfolio and pipeline, marking the beginning of a new era of accelerated growth [4] - The acquisition of Halda Therapeutics for $3.05 billion in cash was completed in December 2025, enhancing J&J's capabilities in biotechnology [4]

Core Insights - Johnson & Johnson reported a strong operational sales growth of 5.3% for full-year 2025, reaching $94.2 billion, with U.S. growth at 6.9% and international growth at 3.4% despite challenges from Stelara [1] - The company emphasized a strategic pivot towards higher-growth markets, including plans to separate its Orthopaedics business by mid-2027, and highlighted significant investments in R&D and M&A totaling over $32 billion in 2025 [4] - CEO Joaquin Duato described 2025 as a "catapult year" for accelerated growth, supported by a robust portfolio and pipeline, with expectations for continued growth and improving margins in 2026 [5] Financial Performance - For Q4 2025, net earnings were $5.1 billion, with diluted EPS of $2.10, up from $1.41 a year earlier; adjusted net earnings were $6.0 billion, with adjusted diluted EPS of $2.46, reflecting increases of 21.5% and 20.6% respectively compared to Q4 2024 [2] - Full-year net earnings reached $26.8 billion, with diluted EPS at $11.03, including a $7 billion talc reserve reversal; adjusted net earnings were $26.2 billion, with adjusted diluted EPS of $10.79, both up 8.1% from 2024 [6] Business Segments - In Innovative Medicine, Q4 worldwide sales were $15.8 billion, up 7.9% operationally, with both U.S. and international growth at 7.9%; acquisitions contributed 170 basis points, primarily from Intra-Cellular [7] - Oncology products showed strong performance, with Darzalex sales growing 24.1% in Q4 and over $14 billion in full-year sales; Carvykti generated $555 million in Q4 sales, up 63.2% [7] - MedTech sales in Q4 were $8.8 billion, up 5.8% operationally, driven by cardiovascular growth, including Abiomed and Shockwave [8] Margins and Guidance - Adjusted income before tax as a percentage of sales rose to 28.7% in Q4 from 24.1% a year earlier, with Innovative Medicine margin improving to 36.3% and MedTech margin to 17.4% [10] - For 2026, the company expects operational sales growth of 5.7% to 6.7%, with a midpoint of $100 billion; adjusted EPS guidance is set at $11.28 to $11.48, implying 5.5% growth at the midpoint [13][14] Pipeline and Future Outlook - Management highlighted anticipated regulatory events for 2026, including expected approvals for Icotide in psoriasis and Tecvayli in multiple myeloma [15] - The company is also focusing on its multiple myeloma portfolio, with positive early feedback on Inlexo for bladder cancer and plans for a permanent J-code [16]

Financial Data and Key Metrics Changes - In Q4 2025, worldwide sales reached $24.6 billion, a 7.1% increase despite a 650 basis point headwind from Stelara [17] - For the full year 2025, worldwide sales were $94.2 billion, reflecting a 5.3% increase, with U.S. growth at 6.9% and international growth at 3.4% [18] - Net earnings for Q4 were $5.1 billion, with diluted earnings per share at $2.10, compared to $1.41 a year ago [18] - Full year 2025 net earnings were $26.8 billion, with diluted earnings per share at $11.03, significantly up from $5.79 the previous year [19] Business Line Data and Key Metrics Changes - Innovative Medicine reported Q4 sales of $15.8 billion, a 7.9% increase, with notable growth in oncology and immunology [20] - In oncology, Darzalex grew 24.1%, while Carvykti achieved sales of $555 million with a growth of 63.2% [20] - Immunology saw Tremfya grow 65.4%, while Stelara declined 48.6% due to biosimilar competition [21] - MedTech sales for the year were $34 billion, with operational growth of 5.4%, driven by cardiovascular and surgical segments [13] Market Data and Key Metrics Changes - U.S. sales growth was 7.5% in Q4, while international sales grew by 6.6% [17] - The cardiovascular segment delivered 15% operational sales growth, with Abiomed and Shockwave showing strong performance [13] - Surgical vision grew 10.8%, driven by new product innovations and demand for premium intraocular lenses [24] Company Strategy and Development Direction - The company plans to separate its orthopedics business by mid-2027, focusing on high-growth areas [30] - Investments of over $32 billion in R&D and M&A were made in 2025, including acquisitions of Intra-Cellular Therapies and HALDA Therapeutics [6] - The company aims for double-digit growth by the end of the decade, supported by a strong portfolio and pipeline [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving faster growth in 2026 compared to 2025, with a line of sight to double-digit growth [6] - The company anticipates operational sales growth in 2026 to be between 5.7% and 6.7%, with a midpoint of $100 billion [31] - Management highlighted the strength of their portfolio and pipeline as key drivers for future growth [41] Other Important Information - The company ended 2025 with approximately $20 billion in cash and marketable securities, and $48 billion in debt [30] - A net interest expense of $300 million to $400 million is expected for 2026 [33] - The effective tax rate is projected to be between 17.5% and 18.5% for 2026 [34] Q&A Session Summary Question: Overview of growth prospects and key levers for double-digit growth - Management highlighted the strength of the portfolio and pipeline, focusing on oncology, immunology, and MedTech as key growth areas [40][41] Question: MedTech market dynamics and growth expectations - Management does not expect the loss of ACA subsidies to materially impact MedTech performance, with a focus on clinical capacity driving growth [48] Question: Margin progression and relationship to top-line growth - Management indicated that margin improvements will align with sales growth, with expectations for at least 50 basis points of improvement in 2026 [55] Question: Vision care market health and performance - Management noted strong underlying demand in the contact lens category, with robust growth driven by new product launches [58][59]

Core Viewpoint - Johnson & Johnson (JNJ) is set to announce its fourth-quarter and full-year 2025 results, with a focus on the performance of its Innovative Medicine segment, which includes various blockbuster therapies across multiple disease areas [1] Group 1: Sales Performance - The Innovative Medicine segment experienced a 3.4% organic sales growth in the first nine months of 2025, despite the loss of exclusivity for its multi-billion-dollar product, Stelara [2][10] - The segment recorded over $15 billion in sales for two consecutive quarters, indicating resilience despite the challenges posed by Stelara's loss of exclusivity [2] - JNJ anticipates growth in Q4 driven by increased sales of key products like Darzalex, Tremfya, and Erleada, alongside the rapid adoption of new drugs such as Carvykti and Tecvayli [3][10] Group 2: Competitive Landscape - The launch of several biosimilar versions of Stelara in 2025 has negatively impacted the Innovative Medicines segment's growth, contributing to a decline of 1070 basis points in Q3 [5] - Rising competition in the U.S. market, particularly from new oral therapies, is expected to adversely affect sales of Imbruvica [6] - The redesign of Medicare Part D under the Inflation Reduction Act is also impacting sales of several drugs, including Stelara and Imbruvica [6] Group 3: Future Outlook - Initial sales figures for JNJ's newly approved drug, Imaavy, are anticipated, as it was approved for treating generalized myasthenia gravis in the U.S. and EU [7] - The Innovative Medicines unit is projected to have a compound annual growth rate (CAGR) of around 5% over the next three years [7] Group 4: Competitive Positioning - JNJ's key areas of focus include immunology and oncology, with significant competition from other large drugmakers such as Novartis, AstraZeneca, and AbbVie in oncology, and AbbVie and Amgen in immunology [8] Group 5: Valuation and Performance - JNJ's shares have outperformed the industry over the past year, with a 45.9% increase compared to an 18.4% rise for the industry [11] - The company's shares are currently trading at a price/earnings ratio of 18.03, slightly above the industry average of 17.54 and its five-year mean of 15.65 [12]